The estimated Net Worth of Lawrence E Bloch is at least $1.17 Million dollars as of 6 December 2017. Lawrence Bloch owns over 500,000 units of Infinity Pharmaceuticals stock worth over $11,619 and over the last 12 years he sold INFI stock worth over $0. In addition, he makes $1,161,170 as President and Treasurer at Infinity Pharmaceuticals.
Lawrence has made over 1 trades of the Infinity Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 500,000 units of INFI stock worth $905,000 on 6 December 2017.
The largest trade he's ever made was buying 500,000 units of Infinity Pharmaceuticals stock on 6 December 2017 worth over $905,000. On average, Lawrence trades about 29,412 units every 0 days since 2012. As of 6 December 2017 he still owns at least 580,944 units of Infinity Pharmaceuticals stock.
You can see the complete history of Lawrence Bloch stock trades at the bottom of the page.
Dr. Lawrence (Larry) E. Bloch M.D. J.D. serves as President, Treasurer of the Company. He previously served as our Executive Vice President, Chief Financial Officer and Chief Business Officer from July 2012 to January 2017. Prior to joining Infinity, Dr. Bloch served as Chief Executive Officer of NeurAxon, Inc., a privately held biopharmaceutical company, from 2007 to 2011. Previously, he served as Chief Financial Officer and Chief Business Officer of NitroMed, Inc., a publicly held biopharmaceutical company, from 2004 to 2006. From 2000 to 2004, Dr. Bloch served as Chief Financial Officer, and from 1999 to 2002 as Vice President, Business Development, of Applied Molecular Evolution, Inc., a publicly held biopharmaceutical company. Dr. Bloch began his career as an emergency medicine resident physician at Massachusetts General Hospital and Brigham and Woman’s Hospital. He holds a J.D. from Harvard Law School, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School.
As the President and Treasurer of Infinity Pharmaceuticals, the total compensation of Lawrence Bloch at Infinity Pharmaceuticals is $1,161,170. There are 2 executives at Infinity Pharmaceuticals getting paid more, with Adelene Perkins having the highest compensation of $1,680,860.
Lawrence Bloch is 53, he's been the President and Treasurer of Infinity Pharmaceuticals since 2017. There are 12 older and 5 younger executives at Infinity Pharmaceuticals. The oldest executive at Infinity Pharmaceuticals Inc. is Anthony Evnin, 79, who is the Independent Director.
Lawrence's mailing address filed with the SEC is C/O INFINITY PHARMACEUTICALS, INC., 1100 MASSACHUSETTS AVENUE, FLOOR 4, CAMBRIDGE, MA, 02138.
Over the last 18 years, insiders at Infinity Pharmaceuticals have traded over $485,846,497 worth of Infinity Pharmaceuticals stock and bought 22,639,120 units worth $175,155,554 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Medical Co L.P. Rosebay. On average, Infinity Pharmaceuticals executives and independent directors trade stock every 70 days with the average trade being worth of $14,976. The most recent stock trade was executed by Adelene Q Perkins on 8 September 2023, trading 768,133 units of INFI stock currently worth $15,363.
the mission of infinity pharmaceuticals, inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation. small molecule discovery and development capabilities infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. strategic alliances building on its strengths in innovative small molecule drug discovery and development, infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline. business and scientific expertise the company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business
Infinity Pharmaceuticals executives and other stock owners filed with the SEC include: